Interview

An interview with Professor Irving Boime
Dr Irving Boime is professor in the Departments of Developmental Biology, and Obstetrics and Gynecology, at Washington University of School of Medicine in St. Louis, Missouri. He received his BS in Pharmacy, and the MS and PhD degrees in Pharmacology. He was an American Cancer Society postdoctoral fellow in the laboratory of Dr Philip Leder, one of the "giants" in developing the field of molecular biology. He received a US Public Health Service Research Career Development Award during [1977] [1978] [1979] [1980] [1981] [1982] . He joined the Department of Pharmacology (Now Department of Developmental Biology), at Washington University School of Medicine as an assistant professor in 1972, and remained there ever since.
Dr Boime very cleverly initiated his long-lasting research program on human placental and pituitary gonadotropins by effectively implementing the then emerging molecular biology tools. His research work provided incredible opportunities to study the basic mechanisms of gonadotropin heterodimeric subunit assembly, and the functional roles of individual subunit N-glycan units that govern sorting, secretion, and signal transduction of the glycoprotein hormone family members. In addition, his laboratory provided unprecedented avenues into clinical applications of recombinant human gonadotropins expressed in mammalian cells. His work has been a major influence on researchers working on other pituitary hormones, most prominently, TSH. His visionary approach to basic science truly epitomizes translational outlook from the beginning of his early research career and way before others realized. Indeed, bench work emanated from his laboratory has equally transformed clinical and veterinary reproductive sciences and successfully reached the bedside. As a testimony to this fact, he holds a portfolio of several patents based on his groundbreaking work on gonadotropins and their clinical applications.
Some of the major highlights of Dr Boime's research include: (a) developing recombinant gonadotropin-expressing mammalian cell lines, (b) elucidating the biological roles of N-and O-glycosylation in the glycoprotein family, (c) engineering novel single chain and long acting gonadotropin analogs, and (d) unraveling the mechanisms of differential gonadotropin sorting (constitutive and regulated) and their polarized secretion (basolateral and apical). Often overlooked are his early contributions to the co-and post-translational processing of secretory proteins.
Dr Boime trained numerous graduate and postdoctoral trainees and physician scientists who are now in leadership positions at various institutions all over the world. His current Department of Developmental Biology celebrated Dr Boime's career a few years ago by recognizing his outstanding research contributions. On this occasion, many of his former trainees honored him, and discussed their research at a symposium. They unanimously praised his mentoring and reminisced the encouragement and support they received from him. "Irv," as he is called by those who know him closely agreed to do this interview for Biology of Reproduction.
You were trained in the pharmaceutical sciences and obtained your PhD from the Department of Pharmacology at Washington University, St. Louis. How did you decide to get into molecular biology area after your PhD training? What prompted you not to pursue classical pharmacology oriented research career?
When I graduated from the St Louis college of Pharmacy, I was faced with the choices of working in retail pharmacy or continuing with my education. My wife Melody put aside her priorities and encouraged me to continue my education.
After I finished my PhD, I realized that some of the therapeutic issues of the day, for example, drug induction and drug resistance needed molecular and biochemical approaches at the subcellular level. This was the main reason I decided to pursue my postdoctoral research in molecular biology.
What was your experience working as a postdoctoral fellow in the legendary Leder laboratory?
It was the best training experience of my career. Phils' great insight and clarity in his approach to scientific problems was an enormous asset for me. In addition to mentoring science, he taught me tremendous laboratory organizational skills.
When you started your independent laboratory, why and how did you decide to initiate your research work on human gonadotropins?
A clinical trainee, Lawrence Corash, working across the hall from Phils' laboratory at NIH was isolating and characterizing placental lysosomes. When I told him I accepted a joint appointment in the Ob & Gyn Department at Washington University, he said that I might consider studies on the synthesis of human chorionic gonadotropin and human placental lactogen. Based on his suggestion, I initiated my major work on placental hormones.
You have made a "quantum leap" by expressing human gonadotropins in mammalian cells which closely mimic in vivo glycosylation patterns that occur in gonadotropes. This breakthrough revolutionized the field of reproductive medicine and current treatment protocols at the fertility clinics. Can you describe briefly the background for this critical approach you took?
In the mid 1980s, we realized that to address structure-function issues of glycoprotein hormones, we needed to go beyond cell-free systems. Together with Dr T.V. Ramabhadran at Monsanto and a graduate student in the laboratory, Christopher Corless, we initiated a mammalian transfection system expressing human gonadotropins. This was followed by extensive mutagenesis investigations by another graduate student, Martin Matzuk.
Except for your PhD thesis work and few initial publications, your research work throughout your career has been on gonadotropin synthesis and secretion. How has this incredible and undeterred focus been possible? Was your Institutional support a key factor in this?
Each time, we addressed a problem related to gonadotropins, we ran into unexpected pathways that made us constantly focus and pursue further within the same research area. Since I had a joint appointment in the Department of Obstetrics and Gynecology, their clinical staff supported my projects continuously. Furthermore, these studies led us to excellent collaborations with Jacques Baenziger, Aaron Hsueh, and you.
Your work provided so many fundamental insights into gonadotropin subunit assembly, sorting, secretion, and action. What do you think is the most significant contribution you have made?
Gonadotropins are expressed as individual subunit-encoding genes, that subunit assembly occurs early in the secretory pathway and N-glycan carbohydrate units have site-specific biologic functions.
Did you ever foresee that your bench work will reach the bedside with so much thunderous clinical impact? How did you capitalize on these achievements dealing with intellectual property issues within your home Institute, commercialization, and legal aspects with pharma/biotech companies?
I never took commercialization of our research very seriously until Martin Matzuk convinced me that some of our recombinant plasmids should be patented. This led to license agreements with Organon, The Netherlands. Our technology transfer office helped us navigate through the complexities of intellectual property issues. In the end, it is very satisfying to see our basic science research translated so effectively into the clinic.
You excelled in research, education/training and distinguished yourself as a great mentor to many. How did you balance each of these major activities in your career? Some of your trainees are highly influenced by you and many are constantly in touch with you till today. What is the secret behind your successful mentoring?
As you imply, it is not easy to balance all these activities. I had an inestimable support from my family during the highs and some bumps along the way. That together with side hobbies (for example, I like collecting and trading old time movie memorabilia) helped maintain my focus.
I emphasized to my trainees let hypothesis-drive the science, be scrupulous to the experiments, and be the Devil's Advocate on your data. Never "shy away" from one more control.
I always treated my trainees as equals and was not threatened by their critiques or arguments over the data. I always tried to achieve an atmosphere in my lab that "science is fun."
What do you envision about where reproductive biology research is heading?
I would like to see genome sequencing on individual eggs be more accessible to patients so that we can accurately identify chromosomal abnormalities, and we achieve better success with single embryo transfers. I also hope that orally active gonadotropins could be developed and be available bypassing the current need for multiple injection protocols using recombinant hormones.
Is there any advice you would like to give to trainees in reproductive biology?
The beauty of science is its unpredictability; there are always unexpected data. Be prepared to follow their path. Always follow your instinct and enjoy Science-it is fun. I am reminded of an anecdote in my early career when a faculty member challenged that science should be serious, not fun. I proved that he was absolutely wrong!
